3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-N-[4-(pyrrolidin-1-yl)butyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine | 505059-75-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-N-[4-(pyrrolidin-1-yl)butyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine
• 英文别名: 4-chloro-N-[[3-(4-chloro-phenyl)-4-phenyl-4,5-dihydro-pyrazol-1-yl]-(4-pyrrolidin-1-yl-butylamino)-methylene]-benzenesulfonamide；3-(4-Chlorophenyl)-N''-((4-chlorophenyl)sulfonyl)-N-[4-(pyrrolidin-1-yl)butyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine；5-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-4-phenyl-N'-(4-pyrrolidin-1-ylbutyl)-3,4-dihydropyrazole-2-carboximidamide
• CAS: 505059-75-6
• 化学式: C₃₀H₃₃Cl₂N₅O₂S
• 分子量: 598.596
• InChiKey: LRLWPBQFMHEFCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  40
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  85.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-吡咯烷丁胺 、 3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide 在 五氯化磷 作用下， 以 氯苯 、 二氯甲烷 为溶剂， 反应 17.0h， 以39%的产率得到3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-N-[4-(pyrrolidin-1-yl)butyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine
  参考文献：
  名称：

  Design, Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel Tacrine Derivatives with a Combination of Acetylcholinesterase Inhibition and Cannabinoid CB₁ Receptor Antagonism

  摘要：

  Pyrazolines 7-10 were designed as novel CB1 receptor antagonists, which exhibited improved turbidimetric aqueous solubilities. On the basis of their extended CB1 antagonist pharmacophore, hybrid molecules exhibiting cannabinoid CB1 receptor antagonistic as well as acetylcholinesterase (AChE) inhibiting activities were designed. The target compounds 12, 13, 20, and 21 are based on 1 (tacrine) as the AChE inhibitor (AChEI) pharmacophore and two different CB1 antagonistic pharmacophores. The imidazole-based 20 showed high CB1 receptor affinity (48 nM) in combination with high CB1/CB2 receptor subtype selectivity (> 20-fold) and elicited equipotent AChE inhibitory activity as 1. Molecular modeling studies revealed the presence of a binding pocket in the AChE enzyme which nicely accommodates the CB1 pharmacophores of the target compounds 12, 13, 20, and 21.

  DOI：

  10.1021/jm901614b

文献信息

• USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP2012775A1

  公开（公告）日：2009-01-14
• PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP2026798A1

  公开（公告）日：2009-02-25
• Use of CBx cannabinoid receptor modulators as potassium channel modulators
  申请人：Antel Jochen

  公开号：US20070254863A1

  公开（公告）日：2007-11-01

  Methods of treating one or more medical conditions by administering to a subject in need thereof an effective amount of a CB x modulator having K ATP channel modulating properties are described herein. Also described are methods of using a CB x modulator having K ATP channel modulating properties to treat one or more medical conditions.
• Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
  申请人：Antel Jochen

  公开号：US20070254862A1

  公开（公告）日：2007-11-01

  Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a K ATP channel modulator; and (ii) a CB x modulator. Also described herein are methods of making and using these compositions.
• US7763607B2
  申请人：——

  公开号：US7763607B2

  公开（公告）日：2010-07-27